These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 25413558)

  • 1. Combining antipsychotics; is this strategy useful?
    Christy J; Burnside D; Agius M
    Psychiatr Danub; 2014 Nov; 26 Suppl 1():315-21. PubMed ID: 25413558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Using antipsychotic agents in older patients.
    Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
    Krzystanek M; Krupka-Matuszczyk I
    Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice.
    Goodwin G; Fleischhacker W; Arango C; Baumann P; Davidson M; de Hert M; Falkai P; Kapur S; Leucht S; Licht R; Naber D; O'Keane V; Papakostas G; Vieta E; Zohar J
    Eur Neuropsychopharmacol; 2009 Jul; 19(7):520-32. PubMed ID: 19411165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Metabolic side effects of risperidone in early onset schizophrenia].
    Goeb JL; Marco S; Duhamel A; Kechid G; Bordet R; Thomas P; Delion P; Jardri R
    Encephale; 2010 Jun; 36(3):242-52. PubMed ID: 20620267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary.
    Kane JM; Leucht S; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2003; 64 Suppl 12():5-19. PubMed ID: 14640142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of aripiprazole in treatment-resistant schizophrenia.
    Mossaheb N; Kaufmann RM
    Neuropsychiatr Dis Treat; 2012; 8():235-44. PubMed ID: 22701324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Hepatic tolerance of atypical antipsychotic drugs].
    Dumortier G; Cabaret W; Stamatiadis L; Saba G; Benadhira R; Rocamora JF; Aubriot-Delmas B; Glikman J; Januel D
    Encephale; 2002; 28(6 Pt 1):542-51. PubMed ID: 12506267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Augmenting atypical antipsychotic medications with clozapin].
    Zink M; Dressing H
    Nervenarzt; 2005 Sep; 76(9):1092, 1094-8, 1100-2. PubMed ID: 15782324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review: Combination therapy with non-clozapine atypical antipsychotic medication: a review of current evidence.
    Chan J; Sweeting M
    J Psychopharmacol; 2007 Aug; 21(6):657-64. PubMed ID: 17092976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aripiprazole in schizophrenia and schizoaffective disorder: A review.
    Stip E; Tourjman V
    Clin Ther; 2010; 32 Suppl 1():S3-20. PubMed ID: 20152550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mid-term and long-term efficacy and effectiveness of antipsychotic medications for schizophrenia: a data-driven, personalized clinical approach.
    Glick ID; Correll CU; Altamura AC; Marder SR; Csernansky JG; Weiden PJ; Leucht S; Davis JM
    J Clin Psychiatry; 2011 Dec; 72(12):1616-27. PubMed ID: 22244023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy and tolerability.
    Bishara D; Taylor D
    Drugs; 2008; 68(16):2269-92. PubMed ID: 18973393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The risks and benefits of switching patients with schizophrenia or schizoaffective disorder from two to one antipsychotic medication: a randomized controlled trial.
    Constantine RJ; Andel R; McPherson M; Tandon R
    Schizophr Res; 2015 Aug; 166(1-3):194-200. PubMed ID: 26141142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strategies for transitioning therapy to aripiprazole from other antipsychotics in schizophrenia.
    Wisniewski CS; Robert S
    Ann Pharmacother; 2012; 46(7-8):1097-104. PubMed ID: 22811346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of aripiprazole augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study.
    Muscatello MR; Bruno A; Pandolfo G; Micò U; Scimeca G; Di Nardo F; Santoro V; Spina E; Zoccali RA
    Schizophr Res; 2011 Apr; 127(1-3):93-9. PubMed ID: 21262565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of atypical antipsychotic drug treatment for dementia: a systematic review and meta-analysis.
    Tan L; Tan L; Wang HF; Wang J; Tan CC; Tan MS; Meng XF; Wang C; Yu JT
    Alzheimers Res Ther; 2015; 7(1):20. PubMed ID: 25897331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atypical Anti-Psychotics in Adult Bipolar Disorder: Current Evidence and Updates in the NICE guidelines.
    Poo SX; Agius M
    Psychiatr Danub; 2014 Nov; 26 Suppl 1():322-9. PubMed ID: 25413559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Investigational drugs for anxiety in patients with schizophrenia.
    Garay RP; Samalin L; Hameg A; Llorca PM
    Expert Opin Investig Drugs; 2015 Apr; 24(4):507-17. PubMed ID: 25423603
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.